Skip to main content
SpringerLink
Log in

Systemic chemotherapy for hepatocellular carcinoma

  • Chapter
Primary Liver Cancer in Japan

Abstract

After a promising preliminary report by Olweny et al. was published in 1975 [1], doxorubicin came into use and was considered the most reliable anticancer agent for hepatocellular carcinoma (HCC). However, in recent well-controlled Phase 11 trials which included doxorubicin, it was demonstrated that no active anticancer agent for HCC shows more than a 15% response rate reproducibly [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Olweny CLM, Toya T, Katongole-Mbidde E, Mugerwa J, Kyalwazi SK, Cohen H (1975) Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer 36: 1250–1257

    Article  PubMed  CAS  Google Scholar 

  2. Falkson G, Coetzer B (1987) Chemotherapy of primary liver cancer. In: Okuda K, Ishak KJ (eds) Neoplasms of the liver. Springer-Verlag, Tokyo, pp 331–326

    Google Scholar 

  3. Okamoto E, Yamanaka N, Toyosaka Y, Tanaka N, Yabuki K (1987) Current status of hepatic resection in the treatment of hepatocellular car cinoma. In: Okuda K, Ishak KJ (eds) Neoplasms of the liver. Springer-Verlag, Tokyo, pp 353–363

    Google Scholar 

  4. Okuda K, Ohtsuki T, Obata H, Tominatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56: 918–928

    Article  PubMed  CAS  Google Scholar 

  5. Einhorn LH (1981) Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 41: 3275–3280

    PubMed  CAS  Google Scholar 

  6. Yamasaki S, Hasegawa H, Makuuchi M (1981) Clinicopathological observation of minute liver cancer and the new method of hepatectomy. An Analysis of 27 cases. Acta Hepatol Jpn 22: 1714–1724

    Article  Google Scholar 

  7. Ebara M, Ohto M, Sugiura N, Kita K, Yoshikawa M, Okuda K, Kondo F, Kondo Y (1990) Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. J Gastroenterol Hepatol 5: 616–626

    Article  PubMed  CAS  Google Scholar 

  8. Yamada R, Sato M, Kawabata T, Nakatsuka H, Nakamura K, Takashima S (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148: 397–401

    PubMed  CAS  Google Scholar 

  9. The Liver Study Group of Japan (1990) Primary liver cancer in Japan (ninth report)

    Google Scholar 

  10. WHO (1979) WHO handbook for reporting results of cancer treatment, WHO Offset Publication, No. 48

    Google Scholar 

  11. Oken MM, Greech RH, Horton J, Davis TE, McFadden Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649–655

    Article  PubMed  CAS  Google Scholar 

  12. Okazaki N, Yoshida T, Yoshino M, Okada S, Shimada Y, Moriyama N, Takayasu K (1991) Changes in mode of response to chemotherapy for hepatocellular carcinoma induced by transarterial embolization. A case report. Jpn J Clin Oncol 21: 69–67

    Google Scholar 

  13. Okada S, Okazaki N, Nose H, Ohkura H, Sugano K, Aoki K (to be published) (1992) Evaluation of chemotherapeutic effects for hepatocellular carcinoma based on survival analysis. Acta Hepatol Jpn

    Google Scholar 

  14. Okazaki N, Yoshino M, Yoshida T, Hizikata A, Hasegawa H (1986) Systemic chemotherapy of hepatocellular carcinoma. Jpn J Cancer Chemother 13: 584–1588

    Google Scholar 

  15. Okazaki N, Yoshino M, Yoshida T, Hijikata A (1985) A controlled study of intravenous doxorubicin versus oral tegafur in patients with hepatocellular carcinoma. J Jpn Soc Cancer Ther 20: 556–561

    CAS  Google Scholar 

  16. Tokyo Liver Cancer Chemotherapy Study Group (1985) Phase II study of co-administration of uracil and tegafur (UFT) in hepatocellular carcinoma. Jpn J Clin Oncol 15: 559–562

    Google Scholar 

  17. Yoshino M, Okazaki N, Yoshida T, Kanda Y, Miki M, Oda H, Sasagawa Y, Hayashi S, Hoshimoto N (1989) A phase II study of etoposide in patients with hepatocellular carcinoma by Tokyo Liver Cancer Chemotherapy Study group. Jpn J Clin Oncol 19: 120–122

    PubMed  CAS  Google Scholar 

  18. Yoshida T, Okazaki N, Yoshino M, Ohkura H, Miyamoto K, Shimada Y (1988) Phase II trial of mitoxantrone in patients with hepatocellular carcinoma. Eur J Cancer Clin Oncol 124: 1897–1898

    Article  Google Scholar 

  19. Yoshida T, Okazaki N, Yoshino M, Ohkura H, Shimada Y (1990) Phase II trial of high dose recombinant gamma-interferon in advanced hepatocellular carcinoma. Eur J Cancer 26: 545–546

    PubMed  CAS  Google Scholar 

  20. Okada S, Okazaki N, Nose H, Aoki K, Simada Y (to be published) (1992) Phase II trial of cisplatin for hepatocellular carcinoma. Eur J Cancer

    Google Scholar 

  21. Olweny CLM, Katongole-Mbidde E, Bahendeka S, Otim D, Mugerwa J, Kyalwazi SK (1980) Further experiences in treating patients with hepatocellular carcinoma in Uganda. Cancer 46: 2717–2722

    Article  PubMed  CAS  Google Scholar 

  22. Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, Block JB, Tong M, Chan KK (1984) Doxorubicin (75mg/m2) for hepatocellular carcinoma: Clinical and pharmacokinetic results. Cancer Treat Rep 68: 487–491

    PubMed  CAS  Google Scholar 

  23. Falkson G, Maclntyre JM, Moertel CG, Johnson LA, Scherman RC (1984) Primary liver cancer: An Eastan Cooperative Oncology Group Trial. Cancer 54: 970–977

    Article  PubMed  CAS  Google Scholar 

  24. Lai CL, Wu PC, Chan GCB, Lok ASF, Lin HJ (1988) Doxorubicin verus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62: 479–483

    Article  PubMed  CAS  Google Scholar 

  25. Höchster HS, Green MD, Speyer J, Fazzini E, Blum R, Muggia FM (1985) The efficacy of high-dose 4’Epirubicin ( Epirubicin ): Activity in hepatocellular carcinoma. J Clin Oncol 3: 1535–1540

    PubMed  Google Scholar 

  26. Shiu W, Leung N, Li M, Leug WT, Li AKG (1988) The efficacy of high-dose 4’Epidoxorubicin in hepatocellular carcinoma. Jpn J Clin Oncol 18: 235–237

    PubMed  CAS  Google Scholar 

  27. Davis RB, Van Echo DA, Leone LA, Henderson ES (1986) Phase II trial of mitoxantrone in advanced primary liver cancer. A Cancer Leukemia Group B Study. Cancer Treat Rep 70: 1125–1126

    PubMed  CAS  Google Scholar 

  28. Falkson G, Ryan LM, Johnson LA, Simson IW, Coetzer BJ, Carbone PP, Creech RH, Schutt AJ (1987) A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer 60: 2141–2145

    Article  PubMed  CAS  Google Scholar 

  29. Ohya T, Kikuchi S, Kato K, Takei T, Takeichi M, Nakano S, Watahiki M, Koyama T, Yamamoto M, Komatsu T, Miwa N, Kasugai T, Hisano N, Tuboi Y, Kikuchi S, Tomusa A (1982) Clinical studies of chemotherapy for primary hepatocellular carcinoma. Jpn J Cancer Chemother 9: 1623–1627

    CAS  Google Scholar 

  30. Cavalli F, Rozencweig M, Renard J, Goldhirsch A, Hansen HH (1981) Phase II study of oral VP-16-213 in hepatocellular carcinoma. Eur J Cancer Clin Oncol 17: 1079–1082

    Article  PubMed  CAS  Google Scholar 

  31. Shiu W, Mok SD, Leung N, Li M, Zacharia A, Li A, Martin C (1987) Phase 2 study of high dose etoposide (VP16-213) in hepatocellular carcinoma. Jpn J Clin Oncol 17: 113–115

    PubMed  CAS  Google Scholar 

  32. Ravry MJR, Omura GA, Bartolucii AA, Einhorn L, Kramer B, Davila E (1986) Phase II evaluation of cisplatin in advanced hepatocellular carcinoma and cholangiocarcinoma: A Southern Cancer Study Group Trial. Cancer Treat Rep 70: 311–312

    PubMed  CAS  Google Scholar 

  33. Okazaki N, Yoshino M, Yoshida T (1989) Chemotherapy for hepatocellular carcinoma. Kan Tan Sui 18: 239–242

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, National Cancer Center Hospital, Tsukiji-5-1-1, Chuo-ku, Tokyo, 107, Japan

    Nobuo Okazaki, Shuichi Okada, Haruhiko Nose & Kazunori Aoki

Authors
  1. Nobuo Okazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shuichi Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Haruhiko Nose
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazunori Aoki
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. 1st Department of Surgery, Faculty of Medicine, Kyoto University, 54-Shogoin Kawara-cho, 606, Sakyo-ku, Kyoto, Japan

    Takayoshi Tobe M. D. (Chairman and Professor) (Chairman and Professor)

  2. The First Department of Internal Medicine, Jikei University School of Medicine, 105, Minato-ku, Tokyo, Japan

    Haruo Kameda

  3. Department of Pathology, School of Medicine, Kitasato University, 228, Sagamihara, Japan

    Masahiko Okudaira

  4. First Department of Medicine, School of Medicine, Chiba University, 280, Chiba, Japan

    Masao Ohto

  5. Sanraku Hospital, 2-5 Kanda Surugadai, 101, Chiyoda-ku, Tokyo, Japan

    Yasuo Endo

  6. The Second Department of Surgery, Asahikawa Medical College, Nishikagura 4-5, 078, Asahikawa, Hokkaido, Japan

    Michio Mito

  7. The First Department of Surgery, Hyogo College of Medicine, 663, Nishinomiya, Hyogo, Japan

    Eizo Okamoto

  8. Second Department of Medicine, Kurume University School of Medicine, 830, Kurume, Japan

    Kyuichi Tanikawa

  9. First Department of Pathology, Kurume University School of Medicine, 830, Fukuoka, Japan

    Masamichi Kojiro

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Tokyo

About this chapter

Cite this chapter

Okazaki, N., Okada, S., Nose, H., Aoki, K. (1992). Systemic chemotherapy for hepatocellular carcinoma. In: Tobe, T., et al. Primary Liver Cancer in Japan. Springer, Tokyo. https://doi.org/10.1007/978-4-431-68177-9_29

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-68177-9_29

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-68179-3

  • Online ISBN: 978-4-431-68177-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation